Non-specific malign stromal tumors of testis

Abstract

Aim: In this study, we aimed to share our experiences about patients with miscellaneous non-specific malign stromal tumors of testis.We report the demographic and clinical characteristics and the long-term results in patients with non-specific malign stromal tumorsof testis.Material and Methods: 234 patients with testicular cancer between June 1994 and January 2019 have been evaluated retrospectively.Eleven patients (Dedifferentiated liposarcoma, Diffuse large B-cell lymphoma, Embryonal rhabdomyosarcoma, Adenocarcinomaof the epididymis, Ewing’s sarcoma of the testis, Testicular leiomyosarcoma, Well-differentiated liposarcoma, Paratesticular highgrade sarcoma and Paratesticular malignant mesothelioma) whose data were reached, are taken into the study. Patients’ age, scrotallocalization of symptoms, clinical examination findings, serum tumor marker levels, pathology results and follow-up period wererecorded.Results:The mean age at diagnosis was 43.7 years (range, 18 to 79). 54.5% of the lesions were localized to the right hemiscrotalarea and of 45.4% to the left hemiscrotal area. None of patients had a history of unilateral undescended testis in medical history ortesticular cancer in familial history. Serum tumor markers were normal in all patients. The mean scrotal mass lesion at diagnosis was59.9 mm3 (range, 33 to 138 mm3). 3 or 4 cyles of chemotherapy protocols were administered in necessary cases. Mean follow-upperiod was 80.6 months (range, 12 to 297 months). Tumor recurrence was occured in only two patients (Dedifferentiated liposarcomaand Adenocarcinoma of the epididymis) during the follow-up.Conclusion: Miscellaneous non-specific malign stromal tumors of the testis should be kept in mind especially in middle age grouppatients presented with malign scrotal lesions. Surgical treatment should be aggressive and additional specific treatment accordingto pathology result should be planned without delay. Follow-up protocols are recommended to be tumor specific.